Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Alkermes is bolstering its neuroscience pipeline by acquiring Rodin Therapeutics, a biotech firm developing treatments for diseases caused by synaptic dysfunction. Rodin investors will get $100 million up front and up to $850 million in future payments based on the progress of Rodin’s small molecules, which selectively inhibit histone deacetylase (HDAC) complexes. Alkermes noted that it might prioritize the development of preclinical HDAC inhibitors over Rodin’s lead candidate, RDN-929, which is in Phase I studies.
This article has been sent to the following recipient: